Abstract

Maintenance of mitochondrial integrity is critical for normal cellular homoeostasis. Most cells respond to stress stimuli and undergo apoptosis by perturbing mitochondrial structure and function to release proteins, such as cytochrome c, which are essential for the execution of the intrinsic apoptotic cascade. Cancer cells evade these events by overexpressing the anti-apoptotic BCL-2 family of proteins on mitochondrial membranes. Inhibitors of the anti-apoptotic BCL-2 family proteins, also known as BH3 mimetics, antagonise the pro-survival functions of these proteins and result in rapid apoptosis. Although the precise mechanism by which BH3 mimetics induce apoptosis has been well characterised, not much is known in terms of the structural changes that occur in mitochondria during apoptosis. Using a panel of highly selective BH3 mimetics and a wide range of cell lines, we demonstrate that BH3 mimetics induce extensive mitochondrial fission, accompanied by swelling of the mitochondrial matrix and rupture of the outer mitochondrial membrane. These changes occur in a BAX/ BAK-dependent manner. Although a major mitochondrial fission GTPase, DRP-1, has been implicated in mitochondrial apoptosis, our data demonstrate that DRP-1 might function independently/downstream of BH3 mimetic-mediated mitochondrial fission to facilitate the release of cytochrome c and apoptosis. Moreover, downregulation of DRP-1 prevented cytochrome c release and apoptosis even when OPA1, a protein mediating mitochondrial fusion, was silenced. Although BH3 mimetic-mediated displacement of BAK and other BH3-only proteins from BCL-XL and MCL-1 was unaffected by DRP-1 downregulation, it prevented BAK activation significantly, thus placing DRP-1 as one of the most critical players, along with BAX and BAK, that governs BH3 mimetic-mediated cytochrome c release and apoptosis.

Highlights

  • Most chemotherapeutic agents kill cancer cells by executing the intrinsic apoptotic pathway, which is characterised by mitochondrial outer membrane permeabilization (MOMP), release of cytochrome c from the innerOfficial journal of the Cell Death Differentiation AssociationMilani et al Cell Death Discovery (2019)5:117 to displace the BH3-only proteins, activate BAX and BAK, thereby inducing MOMP and apoptosis of cancer cells[5].ABT-737, and its orally available analogue, ABT-263 (Navitoclax) were the first bona fide BH3 mimetics developed to target BCL-2, BCL-XL and BCL-w6,7

  • We have reported that BH3 mimetics induce a novel paradigm of apoptosis characterised by marked ultrastructural changes in the mitochondria, involving the loss of mitochondrial cristae and the appearance of breaks in the outer mitochondrial membrane (OMM), resulting from mitochondrial matrix swelling[19,20,31]

  • In cell lines that depend for survival almost exclusively on BCL-2 (MAVER-1), BCL-XL-(K562) and MCL-1 (H929)[32], exposure to the relevant BH3 mimetics, such as ABT-199, A-1331852 and A-1210477, respectively, resulted in similar mitochondrial matrix swelling and rupture of the OMM (Fig. 1a–c)

Read more

Summary

Introduction

Most chemotherapeutic agents kill cancer cells by executing the intrinsic apoptotic pathway, which is characterised by mitochondrial outer membrane permeabilization (MOMP), release of cytochrome c from the innerOfficial journal of the Cell Death Differentiation AssociationMilani et al Cell Death Discovery (2019)5:117 to displace the BH3-only proteins, activate BAX and BAK, thereby inducing MOMP and apoptosis of cancer cells[5].ABT-737, and its orally available analogue, ABT-263 (Navitoclax) were the first bona fide BH3 mimetics developed to target BCL-2, BCL-XL and BCL-w6,7. Milani et al Cell Death Discovery (2019)5:117 to displace the BH3-only proteins, activate BAX and BAK, thereby inducing MOMP and apoptosis of cancer cells[5]. (ABT-199 (Venetoclax), S55746), BCL-XL (A-1331852) and MCL-1 (A-1210477, S63845, AMG 176 and AZD5991) have been synthesised[8,9,10,11,12,13,14] These inhibitors, as single agents, have demonstrated much promise in treating a wide variety of haematological malignancies, and have had limited success in combination with conventional chemotherapy against several solid tumours[8,12,13,14,15,16,17].

Methods
Results
Conclusion

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.